Occult HBV reactivation induced by ibrutinib treatment : a case report
(2015) Acta Gastro-Enterologica Belgica — Vol. 78, n° 4, p. 424-426 (2015)
Files
ActaGastroBelg2015HepB.pdf
Restricted Access - Adobe PDF
- 339.53 KB
Details
- Authors
- Abstract
- Ibrutinib is a small molecule that has been recently developped for the treatment of B cell malignancies. Common side effects are diarrhoea, nausea, fatigue, infections, neutropenia and thrombocytopenia. Here we report the first case of Hepatitis B virus reactivation in a 80 years old chronic lymphocytic leukaemia patient receiving ibrutinib, suggesting that such treatment must be associated with HBV screening.
- Affiliations
Citations
Ngoma, P. d. J., Kabamba-Mukadi, B., Dahlqvist, G., Sempoux, C., Lanthier, N., Shindano, T., Van Den Neste, E., & Horsmans, Y. (2015). Occult HBV reactivation induced by ibrutinib treatment : a case report. Acta Gastro-Enterologica Belgica, 78(4), 424-426. https://hdl.handle.net/2078.5/186904 (Original work published 2015)